SecBot SecBot
424B5 ·Filed May 20, 2026

ANVS

Annovis Bio, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed6mo ago SEC0001104659-26-064510
Notable filing: 424B5
Actionable Insight ▼ Bearish

Expect near-term selling pressure as the offering prices at only a 2% discount to market. Monitor for any further capital needs or clinical trial updates that could shift sentiment. The Phase 3 Alzheimer's readout remains the key catalyst, but the financing overhang may persist until data emerges.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.15
T+0 close · May 20, 2026 · via day close
Latest settled
−19.07%
T+60 · $1.74
Vs SPY
−23.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 21 $2.15entry
  2. T+1 · 6mo ago +3.72%α +3.28% · $2.23
  3. T+5 · 6mo ago −11.63%α −13.23% · $1.90
  4. T+20 · 5mo ago −19.53%α −19.87% · $1.73
  5. T+60 · 3mo ago −19.07%α −23.37% · $1.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Annovis Bio is raising approximately $13.8M in net proceeds through a dilutive offering of 7.9M shares and warrants, priced at $1.90/unit (vs. last sale $1.94). The company has a going concern warning with only $14.2M cash (as of Mar 31, 2026) and an accumulated deficit of $181.3M. This capital raise, following a poor Q1 earnings report, underscores acute funding needs and dilutes existing shareholders by ~23% (excluding warrants). Traders should expect near-term price pressure given the minimal premium to market and ongoing cash burn.

Key Facts

  • Offering 7,895,000 shares of common stock plus warrants to purchase up to 7,105,500 shares at $2.25 exercise price, 6-year term
  • Combined offering price $1.90 per unit, net proceeds ~$13.8M
  • Cash and cash equivalents of $14.2M as of March 31, 2026; company believes runway only extends to Q4 2026
  • Going concern warning from independent auditor; accumulated deficit of $181.3M
  • Q1 2026 earnings (filed May 15) showed increased net loss and cash burn

Financial Impact

Dilution of ~23% to existing shareholders from the common stock offering (plus additional dilution from warrants if exercised). Net proceeds of $13.8M will extend cash runway modestly but do not resolve the structural funding shortfall.

dilutioncash runwayoutstanding shares

Risk Factors

  • Immediate dilution and potential further offerings due to insufficient cash runway
  • Clinical trial failure or delay of pivotal Phase 3 AD data
  • Going concern risk if additional capital is not raised

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-064510
Document: 0001104659-26-064510-index-headers.html0001104659-26-064510
Document: 0001104659-26-064510-index.html0001104659-26-064510
Document: 0001104659-26-064510.txt0001104659-26-064510

US Market Status

Market Closed · Opens in 5h 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 20, 2026